Cessatech
Cessatech is a Danish pivotal-stage paediatric biotech company developing first-in-class fixed-dose nasal spray and injectable medicines for acute and emergency care in children. It licenses lead asset CT001 through exclusive US (Ventis/STAQ) and Europe/ex-US (Proveca) commercial partnerships ahead of near-term launches.
- Company typePrivate
- Founded2020
- HeadquartersCopenhagen, Denmark
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cessatech does
Cessatech A/S is a Danish pivotal-stage paediatric biotech company founded in 2020 as a spinout from Rigshospitalet, Copenhagen University Hospital. The company develops first-in-class specialty hospital medicines targeting acute and emergency care needs in children aged 1-17. Its portfolio addresses a documented under-treatment of pediatric pain where IV access is often painful or infeasible and where many current regimens rely on off-label use.
The lead asset, CT001 (Napatrin), is a fixed-dose combination nasal spray containing ketamine and sufentanil, leveraging a synergistic analgesic effect that enables approximately 30% opioid reduction without loss of efficacy. Pivotal trial 0205 enrolled 220 adult patients and final pediatric safety Study 0202 enrolled over 150 children, with top-line results showing 54% responder rate at 15 minutes and 88% at 30 minutes. The pipeline also includes CT002 (intranasal dexmedetomidine for procedural sedation, with EMA-approved PIP), CT003 (topical anaesthetic gel for laceration repair), and CT004 (intravenous melatonin for post-anaesthesia emergence delirium, developed in collaboration with Rigshospitalet). CT001 has received a positive MDR opinion and an EMA PUMA-based MAA was submitted in August 2025.
Cessatech operates a capital-efficient, partnership-driven commercial model with a lean team of fewer than 10 employees. In the US, Ventis Pharma holds exclusive commercialization rights and STAQ Pharma is the manufacturing partner, with 50/50 cost and profit sharing and a projected $200-400M market opportunity within 5 years. In Europe and ex-US markets, Proveca Ltd holds exclusive commercialization rights and is the marketing authorization holder, with Cessatech receiving double-digit royalties plus upfront and milestone payments. The company is publicly listed on the Spotlight Stock Market under the ticker CESSA, having raised approximately DKK 78 million cumulatively since its oversubscribed 2020 IPO.
Cessatech firmographics
Firmographics- Name
- Cessatech
- Legal name
- Cessatech A/S
- Website
- https://cessatech.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Cessatech is a Danish pivotal-stage paediatric biotech company developing first-in-class fixed-dose nasal spray and injectable medicines for acute and emergency care in children. It licenses lead asset CT001 through exclusive US (Ventis/STAQ) and Europe/ex-US (Proveca) commercial partnerships ahead of near-term launches.
- Ownership category
- akta.pro rank
Cessatech industry classification
Industry- Product category
- Pediatric Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA)
- akta.pro secondary industry
- First Aid & Wound Care (HLAIADAM)
Keywords
Where Cessatech is headquartered
LocationHeadquarters
- HQ city
- Copenhagen
- HQ country
- Denmark
- HQ region
- Europe
Offices1 record
Markets served
Cessatech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Product Sales - US Market: Revenue from CT001 sales in the US market through the partnership with Ventis Pharma and STAQ Pharma. Both parties share development costs and net profits equally (50/50). Expected to generate revenue from 2024, though timeline has been extended due to manufacturing validation requirements.
- Licensing Royalties - Europe/Ex-US: Double-digit royalties to Cessatech on net sales in the licensed territory through the exclusive agreement with Proveca for worldwide commercialization excluding US. Proveca is the marketing authorization holder for Europe.
- Upfront and Milestone Payments: Upfront payment upon signature of the Proveca agreement plus potential milestone payments as regulatory and commercial milestones are achieved.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Cessatech product offering
Product offeringCore offering
Cessatech develops first-in-class specialty hospital medicines for children, focused on acute and emergency care. The lead product CT001 (Napatrin) is a fixed-dose combination analgesic nasal spray of ketamine and sufentanil for children aged 1-17 years experiencing acute pain. The pipeline also includes CT002 (procedural sedation nasal spray), CT003 (sterile local anaesthetic gel for laceration repair), and CT004 (intravenous melatonin for emergence delirium).
Product overview
Cessatech is a pivotal-stage paediatric biotech company developing first-in-class specialty hospital medicines for children. The company's portfolio includes four pipeline products: CT001 (Napatrin) is the lead product, a nasal spray for acute pain in children aged 1-17; CT002 is a nasal spray for procedural sedation during MRI scans; CT003 is a topical anaesthetic gel for laceration repair; and CT004 is an intravenous melatonin formulation for emergence delirium. The company operates a capital-efficient, partnership-driven model with lead product CT001 advancing toward near-term commercialization in both US and European markets.
Differentiator
Problem solved
Functional benefit
Products and services
- CT001 (Napatrin) Fixed-dose analgesic nasal spray combining ketamine and sufentanil for acute pain relief in children aged 1-17 years. Non-invasive, needle-free formulation with fast onset, designed for children experiencing acute pain or pain related to medical procedures.
- CT002 Non-invasive nasal spray containing dexmedetomidine for conscious sedation of children undergoing medical procedures such as MRI scans and diagnostic imaging.
- CT003 Topical anaesthetic gel for paediatric laceration repair. Ready-to-use, sterile, needle-free local anaesthetic gel intended for application in open wounds prior to suturing in emergency departments.
- CT004 Preservative-free intravenous formulation of melatonin for prevention and management of emergence delirium in children following general anaesthesia. Designed to stabilize sleep-wake cycle during post-operative recovery without causing deep sedation or respiratory depression.
Quantifiable outcome
- 54% of patients reported pain relief (pain score ≤4/10) after 15 minutes
- +4 more outcomes
Companies that use Cessatech
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles2 records
Cessatech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Cessatech partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- University Hospital of Copenhagen, RigshospitaletcoreCollaboration to advance CT004 (intravenous melatonin for emergence delirium) in children. Phase II study (MELA-PAED) of 676 children at five sites in Denmark initiated and funded by Rigshospitalet. Cessatech retains worldwide commercial rights to CT004. Jointly outlining regulatory strategy and final development plan.
- STAQ PharmacoreUS manufacturing partner for CT001. FDA registered outsourcing facility with strong sterile manufacturing capabilities and extensive nasal spray expertise. Collaborates with leading pediatric hospitals across the US. Successfully completed technology transfer and development batches with stability studies ongoing.
- Proveca LtdcoreExclusive agreement for commercialization of CT001 worldwide excluding US. Proveca is a global pharmaceutical company specializing in medicines for children. Holds marketing authorization and leads PUMA submission to EMA. Terms include upfront payment and double-digit royalties to Cessatech on net sales. Proveca also has non-exclusive option to license CT002 program.
- Ventis Pharma CorporationcoreExclusive US co-development and commercialization royalty license agreement. Both parties share development costs and net profits equally (50/50). Market opportunity projected at $200-400 million within 5 years. Potential for revenues from 2024. Ventis focuses on innovative pain management therapies and distributes through early access program.
Scale indicators12 records
Recent moves8 records
Expansion highlights6 records
Cessatech competitors and assessment
Company assessmentDirect peers
- Proveca Ltd: UK-based specialty pharmaceutical company exclusively focused on paediatric medicines. Direct peer given its paediatric-only therapeutic focus and exclusive ex-US commercialisation partnership with Cessatech for CT001.
- Neurelis Inc: US specialty pharma that developed Valtoco, an intranasal diazepam spray for paediatric seizure rescue. Directly comparable as a small company commercialising a nasal-spray paediatric CNS drug through hospital and specialty channels.
- Advicenne: French specialty pharma developing paediatric neurology and nephrology products for hospital use. Comparable as a small European paediatric specialty pharma operating in adjacent paediatric CNS/renal categories.
Broad incumbents
- BioMarin Pharmaceutical: Large established paediatric rare-disease biopharma. Comparable as a profitable, hospital-channel paediatric drug developer, though at vastly greater scale and with a broader portfolio than Cessatech's focused pipeline.
- Swedish Orphan Biovitrum (Sobi): Swedish-headquartered specialty biopharma with a dedicated paediatric and rare-disease franchise distributed through hospital channels. Comparable European peer operating in adjacent paediatric specialty categories.
- Jazz Pharmaceuticals: Acquired GW Pharmaceuticals and now markets paediatric neurology products (e.g., Epidiolex) through hospital and specialty pharmacy channels. Broad incumbent in paediatric neurology, an adjacent therapeutic area.
- Recordati Rare Diseases: Specialty pharma division of Recordati operating in rare and paediatric diseases, distributing hospital-administered products globally. Comparable as a European-headquartered paediatric/rare-disease specialty commercial platform.
- Acadia Pharmaceuticals: US specialty pharma commercialising CNS therapies including paediatric neurology assets. Comparable as a hospital- and specialty-channel CNS drug developer in adjacent paediatric indications.
Emerging players
- Ascendis Pharma A/S: Danish specialty biopharma developing rare-disease endocrine therapies including paediatric endocrinology products. Comparable as a Danish paediatric-focused drug developer with hospital-administered products, and a connection to Cessatech's board (Flemming Steen Jensen, SVP).
- Aculys Pharma: Japan-based clinical-stage specialty pharma focused on neurology and rare diseases including paediatric indications. Comparable as a small-cap specialty pharma developing CNS therapies for hospital administration.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Cessatech social profiles
Digital presenceCessatech compliance and trust
Trust signalCompliance2 records
Cessatech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cessatech leadership team
Management profileNumber of profiles
Profiles12 records
Cessatech funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cessatech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cessatech
What does Cessatech do?
Cessatech develops first-in-class specialty hospital medicines for children, focused on acute and emergency care. The lead product CT001 (Napatrin) is a fixed-dose combination analgesic nasal spray of ketamine and sufentanil for children aged 1-17 years experiencing acute pain. The pipeline also includes CT002 (procedural sedation nasal spray), CT003 (sterile local anaesthetic gel for laceration repair), and CT004 (intravenous melatonin for emergence delirium).
Is Cessatech a public or private company?
Cessatech is a private company. It is classified as public and is currently operating.
When was Cessatech founded?
Cessatech was founded in 2020. It employs 1 to 10 people.
Where is Cessatech based?
Cessatech is headquartered in Copenhagen, Denmark, in the Europe region.
How does Cessatech make money?
Three revenue lines are on record. Product Sales - US Market is the primary driver. The others are licensing Royalties - Europe/Ex-US and upfront and Milestone Payments.
Who are Cessatech's main competitors?
Direct peers on record are Proveca Ltd, Neurelis Inc and Advicenne. Broad incumbents are BioMarin Pharmaceutical, Swedish Orphan Biovitrum (Sobi), Jazz Pharmaceuticals, Recordati Rare Diseases and Acadia Pharmaceuticals. Emerging players are Ascendis Pharma A/S and Aculys Pharma.
Does Cessatech have an API?
No public API is recorded for Cessatech.
What industry is Cessatech in?
Cessatech's product category is Pediatric Pharmaceuticals. Its primary akta.pro industry code is HLAIADAA, Pain Relief & Anti-Inflammatory (Analgesics), with a secondary code of HLAIADAM, First Aid & Wound Care. Its NAICS code is 3254 and its SIC code is 2834.